|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of Akt signaling in resistance to DNA-targeted therapy显示文摘The Akt signal transduction pathway controls most hallmarks of cancer. Activation of the Akt cascade promotes a malignant phenotype and is also widely implicated in drug resistance. Therefore, the modulation of Akt activity is regarded as an attractive strategy to enhance the efficacy of cancer therapy and irradiation. This pathway consists of phosphatidylinositol 3 kinase(PI3K), mammalian target of rapamycin, and the transforming serine-threonine kinase Akt protein isoforms, also known as protein kinase B. DNA-targeted agents, such as platinum agents, taxanes, and antimetabolites, as well as radiation have had a significant impact on cancer treatment by affecting DNA replication, which is aberrantly activated in malignancies. However, the caveat is that they may also trigger the activation of repairing mechanisms, such as upstream and downstream cascade of Akt survival pathway. Thus, each target can theoretically be inhibited in view of improving the potency of conventional treatment. Akt inhibitors, e.g., MK-2206 and perifosine, or PI3K modulators, e.g., LY294002 and Wortmannin, have shown some promising results in favor of sensitizing the cancer cells to the therapy in vitro and in vivo, which have provided the rationale for incorporation of these novel agents into multimodality treatment of different malignancies. Nevertheless, despite the acceptable safety profile of some of these agents in the clinical studies, with regard to the efficacy, the results are still too preliminary. Hence, we need to wait for the upcoming data from the ongoing trials before utilizing them into the standard care of cancer patients. | Abolfazl Avan Ravi Narayan Elisa Giovannetti Godefridus J Peters | 2016 | World Journal of Clinical Oncology2016，7，5： | 12 |
| 2 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer显示文摘Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARClevels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOLFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOLFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microR NAs as predictive biomarkers. | Chiara Caparello Laura L Meijer Ingrid Garajova Alfredo Falcone Tessa Y Le Large Niccola Funel Geert Kazemier Godefridus J Peters Enrico Vasile Elisa Giovannetti | 2016 | World Journal of Gastroenterology2016，22，31： | 4 |
| 3 | Better to be alone than in bad company:The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer显示文摘AIM To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.METHODS We tested three different treatment schemes in four non-small cell lung cancer(NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.RESULTS All treatment schemes showed an antagonistic effect in all cell lines,independent of the cMET status.Despite their different genetic backgrounds,all cell lines(EBC-1,HCC827,H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7.These results were independent of the treatment schedule.CONCLUSION These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC. | Nele Van Der Steen Christophe Deben Vanessa Deschoolmeester An Wouters Filip Lardon Christian Rolfo Paul Germonpré Elisa Giovannetti Godefridus J Peters Patrick Pauwels | 2016 | World Journal of Clinical Oncology2016，7，6： | 2 |
| 4 | Nitric oxide is involved in the letions of the peripheral autonomic neurons observed in the acute phase of experimental trypanosama cruzi infection显示文摘 | Garcia SB Paula JS Giovannetti GS | 1999 | Experimental Parasitology1999，93，4： | 2 |
| 5 | Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry显示文摘 | Honeywell R Yarzadah K Giovannetti E | 2010 | J Chromatogr B Analyt Technol Biomed Life Sci2010，878，1516： | 1 |
| 6 | MicroRNA-21 in pancreatic cancer:correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity显示文摘 | Giovannetti E Funel N Peters G J Del Chiaro M Erozenci LA Vasile E | | 0，，： | 1 |
| 7 | Soil-carpophore in some Italian truffle edo-environm ents显示文摘 | Zanini E Giovannetti G Franchini N etal | 1995 | AgricoItura Mediterranea1995，125，： | 1 |
| 8 | Pharmacogenetic study of patients with advanced non-small cell lung cancer(NSCLC)treated with second-line pemetrexed or pemetrexed-carboplatin显示文摘 | Tiseo M Giovannetti E Tibaldi C | 2012 | Lung Cancer2012，78，1： | 1 |
| 9 | Osteomas of the maxillofacial district:endoscopic surgery verus open surgery显示文摘 | CASTELNUOVO P VALENTINI V GIOVANNETTI F | 2008 | Craniofac Surg2008，19，： | 1 |
| 10 | Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse显示文摘 | Alberto Raggi Ambra Mara Giovannetti Silvia Schiavolin Matilde Leonardi Gennaro Bussone Licia Grazzi Susanna Usai Marcella Curone Paola Fiore Domenico D’Amico | 2014 | Quality of Life Research2014，，4： | 1 |
| 11 | Doping graphene with metal contacts显示文摘 | Giovannetti G Khomyakov P Brocks G | 2008 | Plays Rev Lett2008，101，26： | 1 |
| 12 | Thymidylate synthase inhibitors for non-small cell lung cancer显示文摘 | Galvani E Peters G J Giovannetti E | | 0，，10： | 1 |
| 13 | Evaluation of techniques for measuring vesicular arbuscular mycorrhizal infection in roots 显示文摘 | Giovannetti M Mosse B | 1980 | New Phy- tologist1980，84，： | 1 |
| 14 | Characterization of Everyday Functioning in Mild Cognitive Impairment: A Direct Assessment Approach显示文摘 | Giovannetti Tania Bettcher Brianne Magouirk Brennan Laura Libon David J Burke Marykate Duey Katia Nieves Christine Wambach Denene | 2008 | Dementia and Geriatric Cognitive Disorders2008，，4： | 1 |
| 15 | Serum miR-1290 as a Marker of Pancreatic Cancer—Letter显示文摘 | Adam E. Frampton Jonathan Krell Geert Kazemier Elisa Giovannetti | 2013 | Clinical Cancer Research2013，，18： | 1 |
| 16 | Critical role of lasermicrodissection for genetic,epigenetic and proteomic analysesin pancreatic cancer显示文摘 | Funel N Giovannetti E Pollina LE | 2011 | Expert Rev Mol Diagn2011，11，7： | 1 |
| 17 | Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine 显示文摘 | Giovannetti E Del Taeca M Mey V etal | 2006 | Cancer Res2006，66，7： | 1 |
| 18 | Cellular and pharma cogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells显示文摘 | Giovannetti E Mey V Nannizzi S | 2005 | Mol Pharmacol2005，68，1： | 1 |
| 19 | Changes in CCR5 and CXCR4 expression and betachemokine production in HIV-1 infected patients treated with highly active antiretroviral therapy显示文摘 | PIERDOMINICI M GIOVANNETTI A ENSOLI F | 2002 | J Acquit Immune Defic Syndr2002，29，2： | 1 |
| 20 | Cellular and pharmacogenetics foundation of synergistic interaction ofpemetrexed and gemcitabine in human non-small-cell lung cancer cells 显示文摘 | Giovannetti E Mey V Nannizzi S | 2005 | Mol Pharmacol2005，68，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员